FDA approves Wegovy pill for weight loss, the first daily oral medication of its kind

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.

Novo’s Wegovy pill could be a game-changer, but Lilly is not far behind

Novo Nordisk (NVO) stock gains as the FDA approves the company's Wegovy pill, as Eli Lilly (LLY) awaits FDA review for its orforglipron obesity pill. Read more here.

Eli Lilly, Novo Nordisk file competing new weight-loss drugs with the FDA that could be game changers in obesity medicine

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the FDA for approval on Thursday.

Lilly, Novo lock horns in India's obesity drug race

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit
EconoTimes

Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market

Global pharmaceutical leaders Eli Lilly and Novo Nordisk are intensifying competition in Indias rapidly expanding obesity drug market as they race to secure dominance before lower-cost generic alternatives arrive in
Feedback